Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
ESR1 and lung cancer are reported together in 4 articles.
Gene
ESR1
- HGNC
- HGNC:3467
52articles
52mentions
9variants with confirmed gene link
Most co-reported phenotypes (articles)
breast cancer 22lung cancer 4diabetes mellitus 2intellectual disability 2Alzheimer disease 1COVID-19 1Parkinson disease 1colorectal cancer 1
Reported variants (articles · ClinVar status)
Phenotype
Lung cancer
398articles
398mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
4 records shown · first 60Chemical Composition and Anti-Lung Cancer Activities of Melaleuca quinquenervia Leaf Essential Oil: Integrating Gas Chromatography-Mass Spectrometry (GC/MS) Profiling, Network Pharmacology, and Molecular Docking.
PMID 40573169 | PMCID PMC12196179 | DOI 10.3390/ph18060771 · Pharmaceuticals (Basel, Switzerland) · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | ESR1 | “Network pharmacology identified ESR1, CASP3, PPARG, and PTGS2 as key targets, with MQLEO components engaging apoptosis, inflammation (TNF, IL-17), and estrogen pathways.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “In vitro tests revealed selective cytotoxicity against A549 lung cancer cells (IC50 = 18.09 μg/mL; selectivity index = 4.30), meeting NCI criteria.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CASP3 | “Network pharmacology identified ESR1, CASP3, PPARG, and PTGS2 as key targets, with MQLEO components engaging apoptosis, inflammation (TNF, IL-17), and estrogen pathways.” | 0.98 | hgnc_dict_v1 |
| gene | PPARG | “Network pharmacology identified ESR1, CASP3, PPARG, and PTGS2 as key targets, with MQLEO components engaging apoptosis, inflammation (TNF, IL-17), and estrogen pathways.” | 0.98 | hgnc_dict_v1 |
Molecular mechanisms of phytoconstituents from selected Egyptian plants against non-small cell lung cancer using integrated in vitro network pharmacology and molecular docking approach.
PMID 39888361 | PMCID PMC12263816 | DOI 10.1007/s00210-025-03834-4 · Naunyn-Schmiedeberg's archives of pharmacology · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | ESR1 | “Whereas, androgen receptor (AR), epidermal growth factor receptor (EGFR), and estrogen-sensitive receptor alpha (ESR1) were the most enriched target genes.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Molecular mechanisms of phytoconstituents from selected Egyptian plants against non-small cell lung cancer using integrated in vitro network pharmacology and molecular docking approach.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | AR | “Whereas, androgen receptor (AR), epidermal growth factor receptor (EGFR), and estrogen-sensitive receptor alpha (ESR1) were the most enriched target genes.” | 0.98 | hgnc_dict_v1 |
| gene | EGFR | “Whereas, androgen receptor (AR), epidermal growth factor receptor (EGFR), and estrogen-sensitive receptor alpha (ESR1) were the most enriched target genes.” | 0.98 | hgnc_dict_v1 |
Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor.
PMID 38399423 | PMCID PMC10891917 | DOI 10.3390/ph17020208 · Pharmaceuticals (Basel, Switzerland) · 2024 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | ESR1 | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “IRESSA is FDA-approved for lung cancer, which shares some pathways with breast cancers, clearing the hurdles of multitargeted drugs against breast and lung cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
| gene | PIK3CA | “In our research, we conducted a comprehensive screening using HTVS, SP, and XP, followed by an MM/GBSA computation of human-approved drugs targeting HER2/neu, BRCA1, PIK3CA, and ESR1.” | 0.98 | hgnc_dict_v1 |
Multi-targeted effects of D-carvone against Non-Small Cell Lung Cancer (NSCLC): A network pharmacology-based study.
PMID 38795847 | DOI 10.1016/j.taap.2024.116978 · Toxicology and applied pharmacology · 2024 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | ESR1 | “Further analysis identified 5 core/ hub targets of CN including JAK2, ERK1, ESR1, GSK3B and HSP90AA1.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Multi-targeted effects of D-carvone against Non-Small Cell Lung Cancer (NSCLC): A network pharmacology-based study.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | JAK2 | “Further analysis identified 5 core/ hub targets of CN including JAK2, ERK1, ESR1, GSK3B and HSP90AA1.” | 0.98 | hgnc_dict_v1 |
| gene | GSK3B | “Further analysis identified 5 core/ hub targets of CN including JAK2, ERK1, ESR1, GSK3B and HSP90AA1.” | 0.98 | hgnc_dict_v1 |